Corvus Pharmaceuticals, Inc. (CRVS) completed a $150 million underwritten public offering of common stock and pre‑funded warrants, with Jefferies and Goldman Sachs as lead book‑runners, Mizuho as a bookrunner, and Ladenburg Thalmann as a co‑manager. The deal includes a 30‑day option for underwriters to purchase an additional $22.5 million of shares at the offering price, giving the company flexibility to raise up to $172.5 million if demand warrants it.
The net proceeds will be deployed across working capital, general corporate purposes, capital expenditures, and research and development. A significant portion is earmarked for the Phase 3 peripheral T‑cell lymphoma (PTCL) program and the Phase 2 atopic dermatitis (AD) trial of the company’s flagship ITK inhibitor, soquelitinib. By securing this capital, Corvus aims to extend its cash runway beyond the fourth quarter of 2026, a period during which the company’s prior financial statements indicated a liquidity shortfall.
Prior to the offering, Corvus held $74.4 million in cash and had generated $35.7 million in proceeds from warrant exercises. The company has no revenue and continues to post operating losses, a typical profile for a clinical‑stage biopharma. The public offering is therefore a critical step to maintain financial stability while the company advances its high‑potential pipeline.
The AD Phase 2 trial, which began in the first quarter of 2026 with roughly 200 patients, has already produced encouraging Phase 1 data that showed 75 % of patients achieved EASI 75, a benchmark of clinical efficacy. This data has bolstered investor confidence in soquelitinib’s potential to address unmet needs in both oncology and immunology, positioning the drug as a possible oral therapy for patients resistant to existing treatments such as Dupixent and JAK inhibitors.
CEO Richard A. Miller emphasized the company’s optimism, stating that “results from cohort 4 increase our confidence that soquelitinib could become a leading oral therapy for atopic dermatitis.” He added that the Phase 3 PTCL trial will be a critical milestone for the company’s growth trajectory and that the new capital will enable continued investment in the program.
Investor sentiment was initially buoyant following the positive Phase 1 data, but the announcement of the public offering tempered enthusiasm. Analysts adjusted their outlooks to reflect the dilution impact of the new shares while acknowledging the strategic necessity of the capital raise to sustain the company’s long‑term development plans.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.